Skip to content
Subscriber Only

Trius Therapeutics Initial Offer Raises $50 Million

Trius Therapeutics Inc. raised $50 million in an initial public offering after the developer of antibiotics delayed the IPO last week and cut the size of the sale by more than 40 percent.

The drugmaker priced 10 million shares at $5 each yesterday after originally offering 6 million for $12 to $14, according to a statement and Securities and Exchange Commission filings. The San Diego-based company will use proceeds to fund clinical drug trials and research and development, the filings showed.